First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors
French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sezary syndrome and mycosis fungoides
Innate Pharma provides update from regulatory agencies on lacutamab TELLOMAK trial
The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
Innate Pharma provides update on lacutamab TELLOMAK trial
Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
Innate Pharma releases its financial calendar for 2020
Innate Pharma certified as a Great Place to Work®
Innate Pharma third quarter 2019 report
Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
